Takuya Matsushita - Kobayashi Pharmaceutical Sr Division
| KBYPFDelisted Stock | USD 32.49 0.00 0.00% |
Insider
Takuya Matsushita is Sr Division of Kobayashi Pharmaceutical Co
| Phone | 81 6 6222 0142 |
| Web | https://www.kobayashi.co.jp |
Kobayashi Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0633 % which means that it generated a profit of $0.0633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0968 %, meaning that it generated $0.0968 on every $100 dollars invested by stockholders. Kobayashi Pharmaceutical's management efficiency ratios could be used to measure how well Kobayashi Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Kobayashi Pharmaceutical Co has accumulated 596 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Kobayashi Pharmaceutical has a current ratio of 3.84, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Kobayashi Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Kobayashi Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kobayashi Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kobayashi to invest in growth at high rates of return. When we think about Kobayashi Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kelsey DodsonSmith | Sun Country Airlines | N/A | |
| Jude Bricker | Sun Country Airlines | 50 | |
| M Grabowski | Procter Gamble | 52 | |
| CPA Daley | Artisan Partners Asset | 61 | |
| Jennifer Davis | Procter Gamble | 52 | |
| Fatima Francisco | Procter Gamble | 55 | |
| John CFA | Stepstone Group | 42 | |
| Saloni Multani | Artisan Partners Asset | N/A | |
| Craig Buchholz | Procter Gamble | N/A | |
| Minghua Cai | Yuexiu Transport Infrastructure | 44 | |
| CFA CFA | Artisan Partners Asset | 55 | |
| Kirti Singh | Procter Gamble | N/A | |
| Monica Turner | Procter Gamble | 58 | |
| Jose JD | Stepstone Group | 53 | |
| Jeffrey Mader | Sun Country Airlines | 63 | |
| Victor Aguilar | Procter Gamble | 53 | |
| Markus Strobel | Procter Gamble | N/A | |
| Laura Becker | Procter Gamble | N/A | |
| Shelly McNamara | Procter Gamble | N/A | |
| R Keith | Procter Gamble | 52 | |
| Gregory Mays | Sun Country Airlines | 55 | |
Management Performance
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 |
Kobayashi Pharmaceutical Leadership Team
Elected by the shareholders, the Kobayashi Pharmaceutical's board of directors comprises two types of representatives: Kobayashi Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kobayashi. The board's role is to monitor Kobayashi Pharmaceutical's management team and ensure that shareholders' interests are well served. Kobayashi Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kobayashi Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Takayuki Kimura, Gen Department | ||
| Tetsuji Nishioka, Sr Headquarters | ||
| Yoshihiro Ogawa, Sr Division | ||
| Naoki Ayabe, GM Area | ||
| Satoshi Yamane, Managing Director, Executive Officer, Chief Senior Director of Headquarter Group | ||
| Kazumasa Kobayashi, Chairman of the Board, Chairman of Subsidiary, Representative Director | ||
| Akihiro Kobayashi, President Executive Officer, Representative Director | ||
| Fujito Ohwaki, Sr Division | ||
| Kazuhito Miyanishi, Executive Officer, Director of International Business | ||
| Takuya Matsushita, Sr Division |
Kobayashi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Kobayashi Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 3.94 B | |||
| Shares Outstanding | 76.01 M | |||
| Shares Owned By Insiders | 34.50 % | |||
| Shares Owned By Institutions | 21.77 % | |||
| Price To Earning | 34.29 X | |||
| Price To Book | 2.85 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Kobayashi Pink Sheet
If you are still planning to invest in Kobayashi Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kobayashi Pharmaceutical's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |